Oral macrophage-like cells play a key role in tolerance induction following sublingual immunotherapy of asthmatic mice

Mucosal Immunology

Volumn 4, Issue 6, 2011, Pages 638-647

  Mascarell, L ^a   Saint Lu, N ^a   Moussu, H ^a   Zimmer, A ^a   Louise, A ^b   Lone, Y ^c   Ladant, D ^b   Leclerc, C ^b,d   Tourdot, S ^a   Van Overtvelt, L ^a   Moingeon, P ^a  

^a Stallergenes SA   (France)

^b INSTITUT PASTEUR   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 RETINALDEHYDE DEHYDROGENASE; ADENYLATE CYCLASE; CD11B ANTIGEN; CD4 ANTIGEN; DIPHTHERIA TOXIN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 10; MANNOSE RECEPTOR; OVALBUMIN; RETINAL DEHYDROGENASE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; ASTHMA; CD4+ T LYMPHOCYTE; CELL MIGRATION; CERVICAL LYMPH NODE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EOSINOPHIL COUNT; FEMALE; IMMUNOLOGICAL TOLERANCE; LAMINA PROPRIA; LUNG LAVAGE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE SUBPOPULATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; ORAL MACROPHAGE LIKE CELL; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SMALL INTESTINE MUCOSA; SUBLINGUAL IMMUNOTHERAPY; TH2 CELL;

EID: 80054903500     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2011.28     Document Type: Article

References (58)

1. Liu Y. H. & Tsai J. J. Production of salivary immunoglobulin A and suppression of Dermatophagoides pteronyssinus-induced airway infl ammation by local nasal immunotherapy. Int. Arch. Allergy Immunol. 138 161-168 ( 2005
2. Daniel C. et al. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy 61 812-819 ( 2006 (Pubitemid 43893983)
3. Hisbergues M. et al. In vivo and in vitro immunomodulation of Der p 1 allergen-specifi c response by Lactobacillus plantarum bacteria. Clin. Exp. Allergy 37 1286 - 1295 ( 2007 (Pubitemid 47372298)
4. Mousavi T. Tajik N. Moradi M. & Radjabzadeh M. F. CpG Immunotherapy in Chenopodium album sensitized mice: the comparison of IFN-gammaIL-10 and IgE responses in intranasal and subcutaneous administrations. Clin. Mol. Allergy 6 10 ( 2008
5. Lee S. E. et al. Inhibition of airway allergic disease by co-administration of fl agellin with allergen. J. Clin. Immunol. 28 157-165 ( 2008
6. Hufnagl K. et al. Airway infl ammation induced after allergic polysensitization can be prevented by mucosal but not by systemic administration of poly-peptides. Clin. Exp. Allergy 38 1192-1202 ( 2008
7. + T cells in long-term effi cacy of prophylactic and therapeutic mucosal tolerance induction in mice. Allergy 61 173-180 ( 2006 (Pubitemid 43381826)
8. Faria A. M. & Weiner H. L. Oral tolerance: therapeutic implications for autoimmune diseases. Clin. Dev. Immunol. 13 143-157 ( 2006 (Pubitemid 44950033)
9. Nakamura K. Kitani A. & Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 194 629-644 ( 2001 (Pubitemid 32844773)
10. +CD45RBhigh- induced colitis by a TGF-beta-dependent mechanism. J. Immunol. 170 2516-2522 ( 2003 (Pubitemid 36245641)
11. +CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J. Immunol. 180 7327-7337 (2008)
12. Mascarell L. Van Overtvelt L. & Moingeon P. Novel ways for immune intervention in immunotherapy: mucosal allergy vaccines. Immunol. Allergy Clin. North Am. 26 283-306 ( 2006
13. Razafi ndratsita A. et al. Improvement of sublingual immunotherapy effi cacy with a mucoadhesive allergen formulation. J. Allergy Clin. Immunol. 120 278-285 ( 2007
14. Mascarell L. et al. A synthetic triacylated pseudo-dipeptide molecule promotes Th1/TReg immune responses and enhances tolerance induction via the sublingual route. Vaccine 26 108-118 ( 2007 (Pubitemid 350213205)
15. Sun J. B. Flach C. F. Czerkinsky C. & Holmgren J. B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit. J. Immunol. 181 8278-8287 ( 2008
16. + T cells. J. Allergy Clin. Immunol. 122 603-609 ( 2008
17. Lombardi V. et al. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specifi c tolerance via the sublingual route. Clin. Exp. Allergy 38 1819-1829 ( 2008
18. Van Overtvelt L. et al. IL-10-inducing adjuvants enhance sublingual immunotherapy effi cacy in a murine asthma model. Int. Arch. Allergy Immunol. 145 152-162 ( 2008
19. Saint-Lu N. et al. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 64 1003-1013 ( 2009
20. Wilson D. R. Torres L. I. & Durham S. R. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev. (2) ( 2003
21. Wilson D. R. Lima M. T. & Durham S. R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60 4-12 ( 2005
22. Pajno G. B. Peroni D. G. Vita D. Pietrobelli A. Parmiani S. & Boner A. L. Safety of sublingual immunotherapy in children with asthma. Paediatr. Drugs 5 777-781 ( 2003 (Pubitemid 37452626)
23. Passalacqua G. Guerra L. Pasquali M. Lombardi C. & Canonica G. W. Effi cacy and safety of sublingual immunotherapy. Ann. Allergy Asthma. Immunol. 93 3-12 ( 2004
24. Penagos M. et al. Effi cacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 - 18 years of age: a meta-analysis of randomizedplacebo-controlleddouble-blind trials. Ann. Allergy. Asthma. Immunol. 97 141-148 ( 2006 (Pubitemid 44272577)
25. Canonica G. et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 64 1-59 ( 2009
26. Dahl R. et al. Effi cacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 118 434-440 ( 2006 (Pubitemid 44160721)
27. Didier A. et al. Optimal doseeffi cacyand safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J. Allergy Clin. Immunol. 120 1338-1345 ( 2007 (Pubitemid 350225683)
28. Wahn U. et al. Effi cacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 123 160-166 ( 2009
29. Horak F. et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J. Allergy Clin. Immunol. 124 471 - 477 477.e1 ( 2009
30. Durham S. R. et al. Long-term clinical efficacy in grass polleninduced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J. Allergy Clin. Immunol. 125 131-138 ( 2010
31. Compalati E. Passalacqua G. Bonini M. & Canonica G. W. The effi cacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 64 1570-1579 ( 2009
32. Moingeon P. Batard T. Fadel R. Frati F. Sieber J. & Van Overtvelt L. Immune mechanisms of allergen-specifi c sublingual immunotherapy. Allergy 61 151-165 ( 2006 (Pubitemid 43381824)
33. Allam J. P. Bieber T. & Novak N. Dendritic cells as potential targets for mucosal immunotherapy. Curr. Opin. Allergy Clin. Immunol. 9 554-557 ( 2009
34. + T cells. Clin. Exp. Allergy 39 1910-1919 ( 2009
35. Baudner B. C. et al. Enhancement of protective effi cacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect. Immun. 70 4785-4790 ( 2002
36. Guermonprez P. et al. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J. Exp. Med. 193 1035-1044 ( 2001 (Pubitemid 32436197)
37. El Azami El Idrissi M. Ladant D. & Leclerc C. The adenylate cyclase of Bordetella pertussis: a vector to target antigen presenting cells. Toxicon 40 1661-1665 ( 2002 (Pubitemid 35379718)
38. Denning T. L. Wang Y. C. Patel S. R. Williams I. R. & Pulendran B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat. Immunol. 8 1086-1094 ( 2007 (Pubitemid 47423756)
39. Sun C. M. et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J. Exp. Med. 204 1775-1785 ( 2007
40. Bohle B. Kinaciyan T. Gerstmayr M. Radakovics A. Jahn-Schmid B. & Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cellsallergen-specifi c T-cell toleranceand immune deviation. J. Allergy Clin. Immunol. 120 707-713 ( 2007 (Pubitemid 47320765)
41. Cosmi L. et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specifi c immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Clin. Exp. Allergy 36 261-272 ( 2006 (Pubitemid 43344707)
42. Ciprandi G. et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann. Allergy Asthma. Immunol. 95 38-44 ( 2005 (Pubitemid 41022771)
43. Savolainen J. Jacobsen L. & Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 61 1184-1190 ( 2006 (Pubitemid 44326353)
44. Scadding G. W. et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specifi c immunoglobulin G4immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin. Exp. Allergy 40 598-606 ( 2010
45. Allam J. P. et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans ' cell type with high constitutive FcepsilonRI expression. J. Allergy Clin. Immunol. 112 141-148 ( 2003
46. Novak N. Bieber T. & Katoh N. Engagement of Fc epsilon RI on human monocytes induces the production of IL-10 and prevents their differentiation in dendritic cells. J. Immunol. 167 797-804 ( 2001 (Pubitemid 32660834)
47. Allam J. P. et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J. Allergy Clin. Immunol. 121 368-374 ( 2008
48. Allam J. P. et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy 63 720-727 ( 2008
49. Larche M. Immune mechanisms of sublingual immunotherapy: are oral Langerhans cells the masters of tolerance? J. Allergy Clin. Immunol. 126 646-647 ( 2010
50. Allam J. P. et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cellsattenuates their maturationand enhances their migratory and TGF-beta1 and IL-10-producing properties. J. Allergy Clin. Immunol. 126 638 - 645 e631 ( 2010
51. Dadaglio G. Moukrim Z. Lo-Man R. Sheshko V. Sebo P. & Leclerc C. Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis. Infect. Immun. 68 3867-3872 ( 2000 (Pubitemid 30434534)
52. +-T-Cell epitope into the major histocompatibility complex class II antigen presentation pathway by Bordetella pertussis adenylate cyclase. Infect. Immun. 70 1002-1005 ( 2002 (Pubitemid 34083868)
53. + T cell epitopes and in vivo Th1-polarized T cell priming. J. Immunol. 173 6089-6097 ( 2004 (Pubitemid 39487765)
54. + T-cell responses following delivery of human immunodefi ciency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis. J. Virol. 79 9872-9884 ( 2005 (Pubitemid 41022329)
55. Mascarell L. et al. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specifi c Th1 responses and high affi nity neutralizing antibodies in non human primates. Vaccine 24 3490-3499 ( 2006
56. Saraiva M. & O ' Garra A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10 170-181 ( 2010
57. Han C. Jin J. Xu S. Liu H. Li N. & Cao X. Integrin CD11b negatively regulates TLR-triggered infl ammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat. Immunol. 11 734-742 ( 2010
58. Francis J. N. et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J. Allergy Clin. Immunol. 121 1120-1125 e1122 ( 2008